A Randomised, Placebo-controlled, Double-blind Phase II of Sequential Administration of Tarceva (Erlotinib) or Placebo in Combination With Gemcitabine/Platinum as First-line Treatment in Patients With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC).

Trial Profile

A Randomised, Placebo-controlled, Double-blind Phase II of Sequential Administration of Tarceva (Erlotinib) or Placebo in Combination With Gemcitabine/Platinum as First-line Treatment in Patients With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC).

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jan 2015

At a glance

  • Drugs Erlotinib (Primary) ; Carboplatin; Cisplatin; Gemcitabine
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms FAST-ACT
  • Sponsors Roche
  • Most Recent Events

    • 05 Dec 2013 New source identified and integrated: ClinicalTrials.gov record.
    • 23 Feb 2010 Status changed from active, no longer recruiting to completed as reported by Roche.
    • 08 Sep 2009 Results published in the Journal of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top